Covis Pharma has declined to commit to conducting a new randomized, placebo-controlled trial Makena (hydroxyprogesterone caproate injection, also known as 17-OHPC or 17P) if the US Food and Drug Administration orders the preterm birth prevention drug off the market.
At the second day of a hearing on the Center for Drug Evaluation and Research’s proposal to withdraw Makena’s accelerated...






